Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

NCT04468282 is registered in ClinicalTrials.gov with Orphelia Pharma as lead sponsor.

NCT NCT04468282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04468282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration
Lead sponsor
Orphelia Pharma
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2017
Completion date
August 8, 2017
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

therapeutic equivalency